The egg-based production process might have made this season's flu shot only 10% effective.

A Sanofi exec defended its dengue shot in the Philippines on Monday as new reports showed local experts had warned against a broad vaccination push.

Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.

Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.

Here's some other vaccine news of note for the week.

On the heels of a safety warning, the Philippines' FDA ordered Sanofi to pull its Dengvaxia shot from the market.

The Philippines halted its dengue vaccination program after Sanofi flagged serious risks for recipients who'd never been infected with the virus.

Already reeling from bad news on its dengue shot, Sanofi canned its phase 3 C. diff vaccine—and the $500 million-plus in sales that might have come with it.

Johnson & Johnson and partners on Thursday pushed their promising "mosaic" HIV vaccine candidate into efficacy testing.